Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Aniline Compounds
  • Antineoplastic Agents
  • Lung Neoplasms
  • Proto-Oncogene Proteins c-bcl-2
  • Small Cell Lung Carcinoma
  • Sulfonamides

abstract

  • Bcl-2 targeting by navitoclax shows limited single-agent activity against advanced and recurrent SCLC. Correlative analyses suggest several putative biomarkers of clinical benefit. Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics. Future studies will focus on combination therapies.

publication date

  • June 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3715059

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-3090

PubMed ID

  • 22496272

Additional Document Info

start page

  • 3163

end page

  • 9

volume

  • 18

number

  • 11